BactiVax (anti-Bacterial Innovative Vaccines) is an innovative European Training Network that will provide high-level training in vaccinology to 15 high-achieving, creative Early Stage Researchers (ESRs), and equip them with a wide range of transferrable skills for thriving careers in vaccine research within academia and industry. BactiVax will focus on developing novel vaccines to tackle the huge challenge of antimicrobial-resistant human pathogens that cause chronic, life-threatening respiratory and/or systemic infections. This network comprises 14 Principal Investigators with expertise in vaccinology, proteomics, medicine, microbiology, biochemistry, immunology, structural biology, medicinal, peptide and glycochemistry from 9 European countries and two companies which will collectively train ESRs in entrepreneurship, commercial vaccine development and bioprocessing.
The World Health Organisation has identified antimicrobial resistance (AMR) as one of the three greatest threats to mankind. There is a urgent need to train innovative ESRs in the development of new vaccines against AMR infections. BactiVax will tackle the societal challenge caused by the emergence of AMR pathogens and have significant impact on pathogens causing chronic, life-threatening respiratory and/or systemic infections. BactiVax training will cover critical areas of vaccinology from early antigen discovery to optimisation of host response and delivery of vaccine antigens. It will also encompass the increasing problem of vaccine hesitancy in its public engagement. The specific research objectives are to:
1) Identify novel, protective vaccine antigens against target pathogens;
2) Optimise the host response to vaccines;
3) Optimise vaccine delivery;
4) Lead on vaccine advocacy.
Overall, BactiVax will provide ESRs with rich experience and advanced multidisciplinary skills in the cutting edge area of vaccines.
Coordinator: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (Ireland)
Institute of Biostructures and Bioimaging - NATIONAL RESEARCH COUNCIL (Italy);
THE QUEEN'S UNIVERSITY OF BELFAST (United Kingdom);
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS (Spain);
ST GEORGE'S HOSPITAL MEDICAL SCHOOL (United Kingdom);
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (Germany);
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (Italy);
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (United Kingdom);
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (Switzerland);
EOTVOS LORAND TUDOMANYEGYETEM (Hungary);
LIONEX GMBH (Germany);